This systematic review with meta-analysis sought to determine the impact of antioxidants (N-acetylcysteine [NAC], polyunsaturated fatty acids [PUFAs] and vitamins) on incidence of postoperative atrial fibrillation (POAF) and duration of length of hospital stay. Medline, Embase, Elsevier, Sciences online database and Google Scholar literature search was made for studies in randomized controlled trials. The effect sizes measured were odds ratio (OR) for categorical variable and standard mean difference (SMD) with 95% confidence interval (CI) for calculating differences between mean values of duration of hospitalization in intervention and control groups. A value of P < 0.1 for Qtest or I 2 > 50% indicated significant heterogeneity between the studies. Literature search of all major databases retrieved 355 studies. After screening, a total of 23 trials were identified that reported outcomes of 4278 patients undergoing cardiac surgery. Pooled effects estimates on POAF showed a significant reduction after NAC (OR: 0.56, 95% CI: 0.40-0.77, P < 0.001), PUFA (OR: 0.84, 95% CI: 0.71-0.99, P = 0.03) and vitamin C treatment (OR: 0.50, 95% CI: 0.27-0.91, P = 0.02). Hospital length of stay was not reduced after NAC therapy (SMD: 0.082, 95% CI −0.09 to 0.25, P = 0.3), but could be decreased with PUFA (SMD: −0.185, 95% CI: −0.35 to −0.018, P = 0.03) and vitamin C (SMD: −0.325, 95% CI −0.50 to −0.14, P < 0.01). In conclusion, perioperative antioxidant supplementations with NAC, PUFA and vitamin C prevent atrial fibrillation after cardiac surgery. Moreover, PUFA and vitamin C are capable to reduce hospital stay, whereas NAC lacks this capacity.
INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia after cardiac surgery. Incidence of AF has been reported in 20-50% of patients following coronary artery bypass grafting (CABG) and is even higher after combined CABG and valve surgery [1] . AF commonly occurs in the early postoperative period and may result in short-and long-term morbidity and mortality. Risk factors for induction of postoperative AF (POAF) include advanced age, male sex, body mass index >30, atrial dilatation, prolonged aortic crossclamp times, preoperative leucocytosis and increased postoperative plasma levels of proinflammatory markers [1] . POAF may increase stroke rates, trigger haemodynamic instability with heart failure, increase thromboembolic events and consequently lead to prolonged stay on the intensive care unit (ICU) and in hospital, thereby resulting in increase of medical care costs [1] .
The efficacy of pharmacological interventions on preventing POAF has been extensively investigated. Administration of an antiarrhythmic drug for prevention or treatment of POAF can reduce the incidence and recurrence rate of AF. However, the efficacy of a single drug is often limited and all antiarrhythmic therapies have significant limitations in the postoperative period [2] . Thus, the optimal therapeutic approach to prevent POAF and to decrease the hospital length of stay (LOS) remains to be established.
Previous experimental and clinical studies have reported the potential role of oxidative stress in the pathogenesis of AF. Production of reactive oxygen species is likely involved in the structural and electrical remodelling of the heart [3] . In particular, NADPH oxidase can be activated by known triggers of AF such as angiotensin II and atrial stretch [3] . N-acetylcysteine (NAC), polyunsaturated fatty acids (PUFAs) and antioxidant vitamins have been identified in the past as promising supplementations that may contain or limit oxidative stress to the heart and reduce cardiac arrhythmias [4] [5] [6] . Various studies have reported the efficacies of these supplementations on prevention of POAF in cardiac surgery. However, data from randomized controlled trials (RCTs) are limited and so far largely inconclusive. This systematic review with meta-analysis sought to determine the strength of evidence for antioxidant supplementations in cardiac surgery, including NAC, PUFA and antioxidant vitamins, for prevention of POAF and reduction of hospital LOS after cardiac surgery.
METHODS AND MATERIALS

Literature search
A comprehensive literature search was conducted in major electronic databases (MedlinePubMed, Embase, Elsevier, Sciences online database and Google Scholar) from their inception through 10 August 2013, to identify the RCT that reported the effects of NAC, PUFA and antioxidant vitamins on AF following cardiac surgery. Predefined search terms were 'N-acetylcysteine', 'NAC', 'acetylcysteine', 'mucomyst', 'omega-3 fatty acids', 'polyunsaturated fatty acids', 'fish oil', 'vitamin C', 'ascorbic acid', 'ascorbate', 'vitamin E', 'tocopherol', 'vitamin A' and 'atrial fibrillation', 'arrhythmias', and 'cardiac surgery', 'cardiothoracic surgery', 'heart surgery', 'cardiopulmonary bypass', 'CPB', 'coronary artery bypass graft', 'CABG', 'CAB', 'valve surgery' and 'valvular surgery'. There was no language limitation. All retrieved references lists of the included RCT were also reviewed to determine additional studies not indexed in common databases. Studies were included into the analysis if they met the following criteria: (i) RCT, (ii) adults patients (>18 years) undergoing cardiac surgery, (iii) comparison of NAC, PUFA or antioxidant vitamins with a control group and (iv) studies that reported data on the incidence of POAF. Studies were excluded if they reported nonadult patient populations (<18 years). In addition, abstracts without peer-review publications of manuscripts were not included.
Data extraction and outcome measures
Two investigators (S.A.-H.-S. and M.R.-S.) extracted data independently, and discrepancies were resolved via a consensus standardized abstraction checklist used for recording data in each study. Data retrieved from trials included author's name, type of surgery (CABG, valve or combination surgery), study design, type of controls ( placebo or not), type of blinding (double-blinding or not), details of therapeutic regimens, sample size, mean age and gender. The incidence of POAF and LOS was recorded for each group. The primary effect measure was the incidence rate of POAF during hospital stay or at follow-up. All primary authors' definitions for POAF were accepted and are depicted in Supplementary material, Table S1 for each study. For exploration of heterogeneity among trials, a subgroup analysis of disparities in the patients' characteristics was performed for (i) average age (<65 vs ≥65 years), (ii) percentage of males (<80 vs ≥80%), (iii) mean ejection fraction of left ventricle (≥55 vs <55%), (iv) proportion of administration of beta-blockers and angiotensin-converting enzyme inhibitors (ACE-I), (v) types of surgical procedure (CABG only versus CABG combined valve surgery), (vi) diabetes (≤30 vs >30%) and (vii) hypertension (≤70 vs >70%).
Statistical analysis, publication bias and quality assessment
Data were analysed by STATA version 11.0 utilizing METAN and METABIAS modules. The effect sizes measured were odds ratio (OR) with 95% confidence interval (95% CI) for categorical variable, and for non-categorical data, the standard mean difference (SMD) with 95% CI for calculating differences in LOS between intervention and control groups. OR <1 favour supplementation and OR >1 favour control. A value of P < 0.1 for Q-test or I 2 > 50% indicated significant heterogeneity among studies. Heterogeneity among trials was accounted for by applying a random effect model when indicated. The presence of publication bias was evaluated using the Begg and Egger tests. Quality assessment of RCTs was performed by using the Jadad score [7] . The Jadad score assesses three items, including randomization (0-2 points), blinding of study (0-2 points) and withdrawals and dropouts (0-1 points). Higher scores indicate better reporting ('high' quality: 5; 'good' quality: 3-4; 'poor' quality: 0-2). Results were considered statistically significant at a P-value of <0.05.
RESULT
Literature search strategy and included trials
Literature search retrieved 355 studies from screened databases, of which 332 (93.5%) were excluded after detailed evaluation in the initial review ( Fig. 1) either because of insufficient reporting of endpoints of interest (n = 135) or because of non-cardiac surgical procedure used (n = 197).
The final analysis included 23 RCTs (4278 patients) divided into three sections according to the antioxidative therapy used: a total of 10 RCTs [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 
Study characteristics and effect measures
N-Acetylcysteine. A total of 1026 patients were included from 10 RCTs. Two trials were conducted in Canada [9, 10] , 5 in Turkey [8, [14] [15] [16] [17] , 1 in Iran [13] , 1 in Korea [12] and 1 in Australia [11] ( Table 1 ). Patient population of RCTs ranged from 20 to 240 patients, with a mean age of 63.2 years, 76.8% being males. Type of surgery was CABG in 5 studies (n = 128, 12.4%) [9, 12, [14] [15] [16] and CABG and/or valvular surgery in the remaining 5 RCTs (n = 898, 87.6%) [8, 10-11, 13, 17] . From 1026 patients, 513 cases were allocated to the NAC and 513 cases to the control group. NAC administration regimen is presented in detail in Table 1 , with 8 RCTs using intravenous administration (n = 686, 66.8%) [8, [10] [11] [12] [14] [15] [16] [17] and 2 RCTs using oral administration before surgery (n = 340, 33.2%) [9, 13] .
The overall incidence of POAF was 24.7%, with a range from 5% [16] to 61.7% [10] . POAF occurred in 20.4% (105/513 patients) in the NAC group and was significantly higher with 28.8% (148/513 patients) in the control group (P = 0.002) ( Table 2 ). Pooled treatment effect analysis revealed that NAC therapy significantly reduced the incidence of POAF, with an OR of 0.56 (95% CI: 0.40-0.77, P < 0.001; Fig. 2 ) using a fixed effect model. No significant heterogeneity was observed among RCTs (Q-test = 0.3, I 2 = 15%; P = 0.3).
Only five RCTs (523 patients) reported during hospital LOS [8-9, 12-13, 16] . Mean LOS for all trials was 7.36 ± 3.05 days, with 7.43 ± 3.09 for the NAC and 7.29 ± 3.01 for the control group. Pooled analysis applied a random effects model and revealed that
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NAC supplementation failed to reduce hospital LOS (SMD: 0.082, 95% CI: −0.09 to 0.25; P = 0.3). No heterogeneity was observed in this meta-analysis (Q-test = 1.69, I 2 = 0.0%; P = 0.7). All included studies were of good methodological quality (mean Jadad score: 4; range: 3-5; Table 1 ). In addition, Begg's and Egger's tests showed that there was no publication bias among included RCTs (Begg's test, P = 0.788; Egger's test, P = 0.717).
Polyunsaturated fatty acid. A total of 2687 patients were included from 8 RCTs: 2 were conducted in the USA [18, 24] , 2 in Italy [21] [22] , 1 in Germany [20] , 1 in the UK [23] , 1 in Iceland [19] and 1 in Australia [25] (Table 1 ). Patient population of RCTs ranged from 102 to 1516 patients, with a mean age of 64.17 years, 77.6% being males. Type of cardiac surgery in 4 studies was only CABG (n = 566, 21%) [20] [21] [22] [23] , but CABG and/or valvular surgery in 4 others (n = 2121, 78.9%) [18] [19] [24] [25] . Regimen and type of administration of PUFA is given in Table 1 . Most of the studies used oral PUFA (n = 2585, 96.2%), but the German study administrated PUFA intravenously (n = 102, 3.7%) [20] . The overall incidence of POAF was 31.3%, with a range from 17.4% [22] to 54.14% [19] (Table 2 ). POAF occurred in 29.5% (395/1337 patients) in the PUFA group and was significantly higher, with 33.1% (448/ 1350 patients) in the control group (P = 0.04). Pooled treatment effect analysis revealed that PUFA therapy significantly reduced the incidence of POAF with an OR of 0.84 (95% CI: 0.71-0.99; P = 0.03, Fig. 3 ) using a fixed model. Q-test indicated borderline heterogeneity among studies (P = 0.077), which, however, was not present in the I-square test (45.3%). Moreover, subgroup analysis was performed for exploring the cause of heterogeneity, and indicated that the prevalence of diabetes mellitus was significantly different among treatment groups (Table 3) .
Only three RCTs (555 patients) reported hospital LOS [21] [22] 25] . Mean LOS for all trials was 8.47 ± 5.7 days, with 8.08 ± 4.66 for PUFA and 8.85 ± 6.5 for the control group. Meta-analysis via using fixed effects model reported that PUFA significantly reduced LOS (SMD: −0.185, 95% CI: −0.35 to −0.018; P = 0.03). No significant heterogeneity was observed among RCTs (Q-test = 2.27, I 2 = 11%;
All included studies were of good methodological quality (mean Jadad score: 4; range: 2-5; Table 1 ). In addition, Begg's and Egger's tests showed that there was no publication bias among the included RCTs. (Begg's test, P = 0.322; Egger's test, P = 0.132).
Antioxidant vitamins. A total of 565 patients were included from 5 RCTs: 3 were conducted in the USA [26] [27] 30 ], 1 in Greece [28] and 1 in Iran [29] (Table 1 ). Patient population of RCTs ranged from 24 to 185 patients, with a mean age of 65.17 years, 73.6% being males. In 4 studies, type of surgical procedure was CABG only (n = 541, 95.7%) [26] [27] [28] [29] and in 1 study, it was CABG and/or valve surgery (n = 24, 4.2%) [30] . Treatment regimen and type of administration of vitamins are given in Table 1 . The overall incidence of POAF was 33.9% with a range from 15% [29] to 52.9% [28] . POAF occurred in 27.8% (78/280 patients) in the vitamin C group and was significantly higher with 40% (114/285 patients) in the control group (P = 0.002) ( Table 2) . Pooled treatment effect analysis revealed that vitamin C therapy significantly reduced the incidence of POAF with an OR of 0.50 (95% CI: 0.27-0.91; P = 0.02; Fig. 4 ) using a random model. A significant heterogeneity was present among trials (P = 0.09, χ 2 = 8.01 and I 2 = 50%). Subgroup analysis showed that advanced age was the main cause for heterogeneity among trials (Table 3) .
Four RCTs (479 patients) reported hospital LOS [26, [28] [29] [30] . Mean LOS for all trials was 9.47 ± 5.60 days with 8.91 ± 5.57 for vitamin C and 10.0 ± 5.56 for the control group. Pooled analysis employing a random effects model indicated that vitamin C supplementation significantly reduced LOS (SMD: −0.325, 95% CI: −0.50 to −0.14; P < 0.01) with significant heterogeneity in these trials (I 2 = 60.4%, χ 2 = 7.58; P = 0.056). All included studies were of good methodological quality (mean Jadad score: 3; range: 1-5; Table 1 ). In addition, Begg's and Egger's tests showed that there was no publication bias among included RCTs. (Begg's test, P = 0.624; Egger's test, P = 0.230).
DISCUSSION
AF is the most prevalent arrhythmia after open heart surgery and occurs in nearly 30% of patients undergoing CABG, and in 40 and 50% of patients who underwent valve surgery alone or combined CABG and valve surgery, respectively. POAF may increase stroke and haemodynamic instability, produce thromboembolic events and prolong length of ICU and hospital stay, thereby increasing therapy costs [1] [2] . According to current evidence, oxidative stress plays an important role in pathogenesis of postoperative AF. Production of reactive oxygen species is likely involved in the structural and electrical remodelling of the heart. Therefore, the presence of increased antioxidant activity is linked to a decreased risk for the development of postoperative AF [3] .
NAC is addressed as a free radical scavenger antioxidant agent that can decrease cellular antioxidant damage and counteract the myocardial ischaemia/reperfusion injury. In view of the fact that one of the postoperative AF pathogeneses is oxidative stress, various trials on the antiarrhythmic effect of NAC have been performed [4] . Out of these extensive studies, we selected all 10 RCTs, and analysed them by random effect model, the results of which represented the considerable reduction of POAF. No significant heterogeneity was detected among trials.
In 2012 a meta-analysis was performed by Gu et al. [31] via 8 RCTs in which the efficacy of NAC in decreasing POAF was reported. The difference of their study with our research, however, was that we added two recent RCTs studies as well as analysed data on hospital LOS from five studies. In another report of the study by Aranki et al. [32] , it was asserted that AF can reduce hospitalization stay up to 4.9 days and thus can be regarded as a major predictor of prolonged hospital stay. However, our systematic review indicated that perioperative NAC therapy does not 
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reduce the hospital LOS in cardiac surgery patients. Similarly, pervious review has also reported the lack of effectiveness of NAC on reducing LOS [31] . At this point, it should be noted that fewer number of studies reporting on hospital stay and low sample size in each investigation are likely to have some impact on our results. Therefore, future large-scale trials are needed to allow final interpretation of our results with regard to NAC therapy LOS.
PUFA is another of the antioxidants. Today, several animal and clinical studies have indicated the effectiveness of PUFA in coronary artery disease, arrhythmia and heart failure. Several investigators have reported the effectiveness of PUFA on occurrence of AF after cardiac surgery [5] . A meta-analysis was accomplished by Armaganijan et al. [33] in which 4 RCTs were analysed, and showed that PUFA therapy does not reduce POAF. In a recent further systematic review by He et al. [34] in 2013, 6 RCTs were analysed; it was detected that PUFA can significantly reduce POAF. In our analysis, 8 RCTs were appropriate for inclusion after literature review. Our meta-analysis confirms the antiarrhythmic effects of PUFA on POAF, but heterogeneity was significant in these studies. Subgroup analysis indicated diabetes mellitus as a heterogenic factor. It can be speculated that in diabetic patients, the antiarrhythmic effect of PUFA may be more pronounced. In a study by Sorice et al. [22] , it was identified that PUFA can decrease AF following on-pump CABG but no following off-pump CABG. Moreover, Farquharson et al. [25] have argued that the effect of PUFA on AF after CABG combined valve surgery is better than that following CABG only; they, therefore, underscore the different effects of PUFA that may be dependent on the underlying oxidative burden of different patient populations and during various surgeries. Our subgroup analysis, however, indicated that difference in type of surgery does not bear a significant impact on antiarrhythmic effects of PUFA. In addition, only 3 trials reported data on LOS. Pooled analysis indicated a significant decrease in LOS with PUFA therapy.
There are other groups of antioxidants such as vitamin C and E. Vitamin C acts as a cofactor in enzymatic functions and is essential for metabolic reactions such as collagen and amino acid biosynthesis [35] . This vitamin is a potent antioxidant that defends against oxidative reactions such as free radicals and peroxides [6, 35] . Vitamin E is a natural molecule enjoying anti-inflammatory and antioxidant effect [6] . Various studies investigating the antiarrhythmic effects of vitamins C and E were available after literature search, but for two main reasons, some of these trials were excluded from our analysis: (i) some of the studies reported the concurrent administration of vitamin C and E and, thus, were not appropriate for exact analysis and (ii) some others failed to report the incidence rate of POAF. Therefore, a total of 5 RCTs that examined the effects of vitamin C on POAF were included. A best-evidence topic in cardiac surgery by Rasoli et al. [35] has recognized the possible capacity of vitamins in lowering POAF. We therefore resolved to explore the incidence of POAF and duration of hospital LOS from these 5 included studies and our findings indicated a significant capacity of vitamin C in reducing both POAF and LOS in cardiac surgery. However, significant heterogeneity was observed in those studies and subgroup analysis indicated age as a possible confounder.
There are several limitations in this meta-analysis, including the utilization of cumulative data from summary estimates with an inherent risk of bias. However, employment of rigorous methods was used to account for heterogeneity among trials by subgroup analysis and employment of a random effect model for calculation of effect estimates. Nonetheless, as in every systematic review, the lack of complete data from included trials does not allow exclusion of other possible confounders, including divergent perioperative antiarrhythmic management of patients (treatment bias). Furthermore, publication bias was excluded for all effect estimates by Egger's and Begg's test, thereby strengthening the reliability of our results.
In summary, our comprehensive meta-analysis revealed that NAC, PUFA and vitamin C have potential antiarrhythmic effects and reduce POAF. In addition, PUFA and vitamin C, but not NAC, appear to have the capacity of decreasing hospital LOS. These findings imply that preventing POAF may reduce LOS. Finally, we strongly believe that evidence is now given based on our results for the initiation of a large-scale RCT. Nonetheless, we speculate that receiving funding for such a trial will be difficult in light of the enormous costs and lack of potential commercial benefit.
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